Skip to content

Clinical trials

Completed Precursor Cell Lymphoblastic Leukemia-Lymphoma trials in Italy

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Precursor Cell Lymphoblastic Leukemia-Lymphoma Status: Completed Country / region: Italy Clear all

71 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20013
20034
20042
20057
20061
20073
20081
20092
20103
20112
20125
20136
20143
20154
20162
20172
20182
20192
20201
20212
20222
20241

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed71

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center10
Novartis Pharmaceuticals10
Gruppo Italiano Malattie EMatologiche dell'Adulto9
Amgen6
European Organisation for Research and Treatment of Cancer - EORTC4
Amgen Research (Munich) GmbH3
Bristol-Myers Squibb2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS2
Gamida Cell ltd2
Gruppo Italiano Trapianto di Midollo Osseo2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma71
Leukemia, Myeloid, Acute21
Lymphoma, Non-Hodgkin16
Burkitt Lymphoma15
Hodgkin Disease14
Leukemia, Lymphocytic, Chronic, B-Cell14
Recurrence13
Lymphoma, Large B-Cell, Diffuse12
Multiple Myeloma12
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma12

Trials

Showing 1 to 25 of 71. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.